John T Isaacs
Overview
Explore the profile of John T Isaacs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
5821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Isaacs J, Brennen W, Christensen S, Denmeade S
Molecules
. 2021 Dec;
26(24).
PMID: 34946547
Søren Brøgger Christensen isolated and characterized the cell-penetrant sesquiterpene lactone Thapsigargin (TG) from the fruit In the late 1980s/early 1990s, TG was supplied to multiple independent and collaborative groups. Using...
12.
Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, et al.
Cancer Res
. 2021 Oct;
81(23):5948-5962.
PMID: 34645612
The discovery that androgens play an important role in the progression of prostate cancer led to the development of androgen deprivation therapy (ADT) as a first line of treatment. However,...
13.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J, et al.
Oncogene
. 2021 May;
40(22):3914-3916.
PMID: 33958727
No abstract available.
14.
Christensen S, Simonsen H, Engedal N, Nissen P, Moller J, Denmeade S, et al.
Prog Chem Org Nat Prod
. 2021 Apr;
115:59-114.
PMID: 33797641
Thapsigargin, the first representative of the hexaoxygenated guaianolides, was isolated 40 years ago in order to understand the skin-irritant principles of the resin of the umbelliferous plant Thapsia garganica. The...
15.
Brennen W, Zhu Y, Coleman I, Dalrymple S, Antony L, Patel R, et al.
JCI Insight
. 2021 Mar;
6(8).
PMID: 33724955
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR- neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN,...
16.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J, et al.
Oncogene
. 2021 Feb;
40(11):2148.
PMID: 33564077
No abstract available.
17.
Sena L, Wang H, Lim ScM S, Rifkind I, Ngomba N, Isaacs J, et al.
Eur J Cancer
. 2020 Dec;
144:302-309.
PMID: 33383350
Background: Cyclical, high-dose testosterone administration, termed bipolar androgen therapy (BAT), can induce clinical responses and restore sensitivity to androgen signalling inhibition in patients with previously treated castration-resistant prostate cancer (PCa)...
18.
Brennen W, Thorek D, Jiang W, Krueger T, Antony L, Denmeade S, et al.
Immunotherapy
. 2020 Nov;
13(2):155-175.
PMID: 33148078
The tumor microenvironment contributes to disease progression through multiple mechanisms, including immune suppression mediated in part by fibroblast activation protein (FAP)-expressing cells. Herein, a review of FAP biology is presented,...
19.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J, et al.
Oncogene
. 2020 Sep;
39(45):6935-6949.
PMID: 32989253
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors...
20.
Rogers O, Antony L, Levy O, Joshi N, Simons B, Dalrymple S, et al.
Mol Cancer Ther
. 2020 Sep;
19(11):2353-2362.
PMID: 32943549
PRX302 is a highly potent, mutant bacterial pore-forming biologic protoxin engineered for selective activation by PSA, a serine protease expressed by benign and malignant prostate epithelial cells. Although being developed...